Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sorin launches Ovatio ICDs (implantable cardioverter defibrillators) in Japan:

This article was originally published in Clinica

Executive Summary

Sorin Group has launched its Ovatio DR implantable cardioverter defibrillators (ICDs) in Japan. The Milan, Italy company claims that the Ovatio product line comprises the world's smallest such devices, and hence that their thinness suits for Japanese body size. The single and dual chamber models, Ovatio VR 6250 and DR 6550 ICD, have received regulatory and reimbursement approval from the Japanese health ministry (MHLW). Both models are immediately available. The dual chamber Ovatio DR includes a feature designed to reduce unnecessary stimulation in the right ventricle, thus decreasing the risk of heart failure and atrial fibrillation, as well as a component intended to protect patients from inappropriate shocks.

You may also be interested in...

QUOTED. 27 November 2020. Agam Sharda.

The first trial of the new Flash ultra-high dose radiation therapy with Varian Medical Systems’ ProBeam particle accelerator has begun. Agum Sharda, Varian’s senior director of Flash, says the technology could be a major advance for cancer patients.

Real World Data Failed To Impress Kaftrio’s European Reviewers

The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.

Swissmedic Clears Up Confusion Over Validity Of GMP Certificates

Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts